An announcement from Summit Therapeutics ( (SMMT) ) is now available.
Summit Therapeutics Inc. has revealed promising trial results at the IASLC 2024 World Conference on Lung Cancer, showcasing the efficacy of ivonescimab, a novel therapy for patients with PD-L1-positive advanced non-small cell lung cancer. The data from the HARMONi-2 trial indicates a significant improvement in progression-free survival compared to the existing treatment pembrolizumab. These findings, alongside additional Phase II trial results and upcoming conference discussions, could signal a breakthrough for cancer treatment, pending further regulatory approval beyond China’s NMPA.
For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.
